Blog
RSS FeedPosted by Michael Wonder on 15 Nov 2024
Representativeness of studies required under Medicare’s coverage with evidence development program
13 November 2024 - Medicare beneficiaries are often inadequately represented in clinical studies supporting US Food and Drug Administration medical product ...
Posted by Michael Wonder on 27 Mar 2023
Final reconciliation of savings from side agreements for the full year 2022
28 March 2023 - The TLV has presented the Government with the final reconciliation of the outcome of savings from ...
Posted by Michael Wonder on 25 Mar 2022
Updated procedures and guidelines for company submissions to ACE
25 March 2022 - Version 1.1 of ACE's "Procedures and guidelines for company submissions to the Agency for Care Effectiveness for ...
Posted by Michael Wonder on 19 Mar 2022
Final reconciliation of savings from side agreements for the full year 2021
18 March 2022 - TLV has presented the final reconciliation to the government of the outcome of the rebates in ...
Posted by Michael Wonder on 10 Aug 2021
Characterisation of the pharmaceutical risk sharing arrangement process in Catalonia
10 August 2021 - Pharmaceutical risk sharing arrangements have emerged as a reasonable tool to promote sustainable access to innovative medicines ...
Posted by Michael Wonder on 01 Jul 2021
2021's first forecast of savings from side agreements
28 June 2021 - In a new report to the government, TLV forecasts that the pharmaceutical companies will pay approximately ...
Posted by Michael Wonder on 28 Sep 2020
International experience with performance-based risk-sharing arrangements: implications for the Chinese innovative pharmaceutical market
23 September 2020 - This study aims to summarise the international experience of performance-based risk-sharing arrangements and identify the preconditions for ...
Posted by Michael Wonder on 03 Dec 2019
The use of risk-sharing contracts in health care: theoretical and empirical assessments
3 December 2019 - The aim of this review is to provide a summary of the literature on risk-sharing agreements, including ...
Posted by Michael Wonder on 27 May 2019
NHS England wants money back guarantee on Orkambi
24 May 2019 - Vertex resisting real-world data proposal. ...
Posted by Michael Wonder on 29 Jan 2019
Pfizer launches China's first pay for performance model for cancer
26 January 2019 - Pfizer launched a pay-for-performance insurance program for its breast cancer drug Ibrance palbociclib in China. The ...
Posted by Michael Wonder on 14 Sep 2018
EMA Priority Medicines scheme (PRIME): will more paying-for-performance agreements be needed due to immature data?
14 September 2018 - The EU’s centralized procedure for the authorization of a new drug is performed by the EMA. ...
Posted by Michael Wonder on 02 Jun 2018
Innovative pharmaceutical pricing agreements in five European markets: A survey of stakeholder attitudes and experience
31 May 2018 - Innovative pricing agreements for medicines have been used in European markets for more than 20 years, ...
Posted by Michael Wonder on 03 May 2018
For expensive new drugs, biopharma should make money-back guarantees mandatory
2 May 2018 - In a recent paper on “Value-Based Pricing for Drugs”, authors Anna Kaltenboeck and Peter B. Bach of ...
Posted by Michael Wonder on 28 Mar 2018
In battle to cut drug prices, outcome-based pricing carries big risks for biopharma
28 March 2018 - In a provocative piece entitled “Trump’s Health Secretary Wants To Transform Healthcare. Can He?”, fellow Forbes contributor, ...
Posted by Michael Wonder on 19 Feb 2018
A real world example of coverage with evidence development in Australia - ipilimumab for the treatment of metastatic melanoma
13 February 2018 - Australian Government subsidisation of ipilimumab for the treatment of patients with metastatic melanoma was conditional on the ...